Related Experiment Videos

[Biochemical characterization of tumor rejection antigen (TRA) and genetic control in anti-TRA immune responses]

H Fujiwara1, T Suda, J Shimizu

  • 1Biomedical Research Center, Osaka University Medical School, Japan.

Insights

Researchers isolated a tumor rejection antigen (TRA) from fibrosarcoma cells. This 60 kD antigen, distinct from pp60src, effectively protects against Rous sarcoma virus-induced tumors, offering a potential target for cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Virology

Context:

  • Rous sarcoma virus (RSV) induces fibrosarcoma tumors.
  • Tumor rejection antigens (TRA) are crucial for tumor immunity.
  • Plasma membrane proteins are key targets for immune responses.

Purpose:

  • To isolate and characterize a TRA from RSV-induced fibrosarcoma cells.
  • To investigate the relationship between TRA and pp60src.
  • To assess the immunoprotective potential of the isolated TRA.

Summary:

  • A 60 kD TRA was isolated from RSV-induced fibrosarcoma cells using SDS-extraction.
  • The TRA was found to be distinct from pp60src, as depleting pp60src did not abolish TRA activity.
  • Immunization with the pp60src-depleted TRA fraction conferred potent tumor protection against RSV-induced tumors.

Impact:

  • Identifies a novel TRA distinct from pp60src as a potential target for cancer vaccines.
  • Provides insights into the role of the src gene in TRA expression and immune response.
  • Suggests a strategy for developing immunotherapies against RSV-induced cancers.

Related Concept Videos